Sol-Gel Technologies Ltd., an Israeli pharmaceutical company specializing in dermatology products, achieved significant top-line growth in 2025 driven primarily by licensing deals including U.S. rights licensed to Mayne Pharma. Despite this surge, the company continues to report net losses as heavy investment in research and clinical development persists. Sol-Gel maintains a strong liquidity position with ample cash and marketable securities but faces substantial doubt regarding its ability to sustain operations beyond one year without additional funding. Future growth hinges on successful commercialization, favorable trial outcomes, and securing further capital [F1], [S6], [S21].